Distribution/Logistics

Gene Therapy for Rare Disorders is dedicated to overcoming the unique drug development challenges encountered in transforming gene therapy concepts into reality for rare disease patients in need.As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, Gene Therapy for Rare Disorders provides in-depth insights from experts who know how to drive clinical progress, optimize manufacturing, and demonstrate the value of gene therapy products to regulators, payers, and patients.Across four days, this meeting will unite 500+ leading experts in Boston from innovative biotechs, large pharma, academia, and key service provider companies, delivering actionable insights and valuable networking opportunities to accelerate gene therapy progress.

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 60+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.

Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligonucleotides, peptides, mRNA, drug delivery and partnering strategies — from discovery to market, with an emphasis on the European region.Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.

Industry leaders and service providers share cutting-edge content and company expertise across the oligonucleotide, peptide, MRNA and drug delivery spectrum.

Advance your innovative biologics pipeline and elevate your engineering, targets and machine learning strategies – accelerating your path to the clinic and beyond.

The European Medicines Agency (EMA) have issued a network strategy to 2025 with the mission: Protecting Public Health at a Time of Rapid Change. The strategic focus areas are availability and accessibility of medicines, data analytics-digital tools and digital transformation, innovation, anti-microbial resistance, other emerging health threats, supply chain challenges, sustainability of the network and operational excellence. This sets the framework for the 2022 ISPE Europe Annual Conference in Madrid in April. High level speakers from the European Commission, the European Federation of Pharmaceutical Industries’ Associations (EFPIA) as well as European National Competent Authorities engaged in sustainability will give input to ISPEs well known traditional Executive Forum. Special focus will feature industry speakers on learnings from the COVID-19 crisis and the management of vaccine production and logistics.